Cargando…

Getting CD19 Into Shape: Expression of Natively Folded “Difficult-to- Express” CD19 for Staining and Stimulation of CAR-T Cells

The transmembrane protein CD19 is exclusively expressed on normal and malignant B cells and therefore constitutes the target of approved CAR-T cell-based cancer immunotherapies. Current efforts to assess CAR-T cell functionality in a quantitative fashion both in vitro and in vivo are hampered by the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lobner, Elisabeth, Wachernig, Anna, Gudipati, Venugopal, Mayrhofer, Patrick, Salzer, Benjamin, Lehner, Manfred, Huppa, Johannes B., Kunert, Renate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Bioengineering and Biotechnology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020774/ https://www.ncbi.nlm.nih.gov/pubmed/32117929 http://dx.doi.org/10.3389/fbioe.2020.00049

Ejemplares similares

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
por: Laurent, Elisabeth, et al.
Publicado: (2021)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function
por: Salzer, Benjamin, et al.
Publicado: (2020)

Recombinant Human CD19 in CHO-K1 Cells: Glycosylation Patterns as a Quality Attribute of High Yield Processes
por: Billerhart, Magdalena, et al.
Publicado: (2023)

Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells
por: Zhang, Yuanyuan, et al.
Publicado: (2023)

Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells
por: Mayrhofer, Patrick, et al.
Publicado: (2021)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
por: Nerreter, Thomas, et al.
Publicado: (2019)

SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
por: Garner-Spitzer, Erika, et al.
Publicado: (2022)

CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
por: Fousek, Kristen, et al.
Publicado: (2020)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus
por: Smyth, Mark, et al.
Publicado: (2021)

Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction
por: Ma, Haiting, et al.
Publicado: (2020)

Harnessing CD3 diversity to optimize CAR T cells
por: Velasco Cárdenas, Rubí M.-H., et al.
Publicado: (2023)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives
por: Mayrhofer, Patrick, et al.
Publicado: (2018)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis
por: Hong, Injae, et al.
Publicado: (2015)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Identification of bottlenecks in antibody expression using targeted gene integration
por: Mayrhofer, Patrick, et al.
Publicado: (2015)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

Germinality does not necessarily define mAb expression and thermal stability
por: Schwaigerlehner, Linda, et al.
Publicado: (2019)

TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
por: Li, Guangchao, et al.
Publicado: (2021)

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
por: Cordes, Nicole, et al.
Publicado: (2021)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Topological and Structural Plasticity of the Single Ig Fold and the Double Ig Fold Present in CD19
por: Youkharibache, Philippe
Publicado: (2021)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
por: Zhang, Cheng, et al.
Publicado: (2020)

Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation
por: Garner-Spitzer, Erika, et al.
Publicado: (2023)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
por: Zanetti, Samanta Romina, et al.
Publicado: (2022)

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells
por: Strati, Paolo, et al.
Publicado: (2023)

Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells
por: Mika, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_og0k8cmsmiio926dbtm5krr67b